Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature
Background—Novel oral anticoagulants (NOACs) have been proposed as alternatives to
vitamin K antagonists for the prevention of stroke and systemic embolism in patients with …
vitamin K antagonists for the prevention of stroke and systemic embolism in patients with …
Aetiology, secondary prevention strategies and outcomes of ischaemic stroke despite oral anticoagulant therapy in patients with atrial fibrillation
AA Polymeris, TR Meinel, H Oehler… - Journal of Neurology …, 2022 - jnnp.bmj.com
Objective To investigate the aetiology, subsequent preventive strategies and outcomes of
stroke despite anticoagulation in patients with atrial fibrillation (AF). Methods We analysed …
stroke despite anticoagulation in patients with atrial fibrillation (AF). Methods We analysed …
Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease
M Kimachi, TA Furukawa, K Kimachi… - Cochrane Database …, 2017 - cochranelibrary.com
Background Chronic kidney disease (CKD) is an independent risk factor for atrial fibrillation
(AF), which is more prevalent among CKD patients than the general population. AF causes …
(AF), which is more prevalent among CKD patients than the general population. AF causes …
[HTML][HTML] 2017 consensus of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation
CE Chiang, K Okumura, S Zhang, TF Chao, CW Siu… - Journal of arrhythmia, 2017 - Elsevier
Atrial fibrillation (AF) is the most common sustained arrhythmia, causing a 2-fold increase in
mortality and a 5-fold increase in stroke. The Asian population is rapidly aging, and in 2050 …
mortality and a 5-fold increase in stroke. The Asian population is rapidly aging, and in 2050 …
[PDF][PDF] Guía ESC 2016 sobre el diagnóstico y tratamiento de la fibrilación auricular, desarrollada en colaboración con la EACTS
S Benussi, D Kotecha, A Ahlsson… - Rev Esp …, 2017 - sedeelectronica.comcordoba.com
Se recomienda a los profesionales de la salud que tengan en consideración la presente
guía de la ESC/EACTS en la toma de decisiones clínicas en su ejercicio diario, así como en …
guía de la ESC/EACTS en la toma de decisiones clínicas en su ejercicio diario, así como en …
Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2
The choice of oral anticoagulant (OAC) for patients with atrial fibrillation (AF) may be
influenced by individual clinical features or by patterns of risk factors and comorbidities. We …
influenced by individual clinical features or by patterns of risk factors and comorbidities. We …
Paradoxical embolism
S Windecker, S Stortecky, B Meier - Journal of the American College of …, 2014 - jacc.org
Paradoxical embolism is an important clinical entity among patients with venous
thromboembolism in the presence of intracardiac or pulmonary shunts. The clinical …
thromboembolism in the presence of intracardiac or pulmonary shunts. The clinical …
Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation …
JAC Sterne, PN Bodalia, PA Bryden… - Health Technology …, 2017 - discovery.ucl.ac.uk
BACKGROUND: Warfarin is effective for stroke prevention in atrial fibrillation (AF), but
anticoagulation is underused in clinical care. The risk of venous thromboembolic disease …
anticoagulation is underused in clinical care. The risk of venous thromboembolic disease …
2021 Focused update of the 2017 consensus guidelines of the Asia Pacific Heart Rhythm Society (APHRS) on stroke prevention in atrial fibrillation
The consensus of the Asia Pacific Heart Rhythm Society (APHRS) on stroke prevention in
atrial fibrillation (AF) has been published in 2017 which provided useful clinical guidance for …
atrial fibrillation (AF) has been published in 2017 which provided useful clinical guidance for …
A support programme for secondary prevention in patients with transient ischaemic attack and minor stroke (INSPiRE-TMS): an open-label, randomised controlled trial
M Ahmadi, I Laumeier, T Ihl, M Steinicke… - The Lancet …, 2020 - thelancet.com
Background Patients with recent stroke or transient ischaemic attack are at high risk for a
further vascular event, possibly leading to permanent disability or death. Although evidence …
further vascular event, possibly leading to permanent disability or death. Although evidence …